Strategic Partnership LimFlow is now part of Stryker, presenting a strong channel for co-selling, broader distribution, and access to Stryker’s global sales force and customer base in vascular and limb preservation markets.

Clinical Validation Positive clinical indicators such as amputation-free survival and wound healing from the PROMISE I study support a compelling value proposition for hospitals seeking alternatives to major amputations in CLTI patients.

Economic Reimbursement Leadership hires focused on health economics and reimbursement plus ongoing collaborations suggest a path to faster payer acceptance and favorable reimbursement coverage for the LimFlow System.

Market Readiness Recent financing rounds and Series D funding, alongside ongoing trials and NAMSA partnerships, imply a maturing product ready for broader commercialization and multi-site adoption.

Targeted Segments Focus on end-stage CLTI patients with limited options and MIN invasive approach positions LimFlow to target high-need hospitals, vascular centers, and wound care networks seeking limb-salvage therapies.